Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Tonix Pharmaceuticals Holding (TNXP) EBT: 2017-2024

Historic EBT for Tonix Pharmaceuticals Holding (TNXP) over the last 8 years, with Dec 2024 value amounting to -$136.7 million.

  • Tonix Pharmaceuticals Holding's EBT fell 101.02% to -$31.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$98.0 million, marking a year-over-year increase of 30.87%. This contributed to the annual value of -$136.7 million for FY2024, which is 39.20% down from last year.
  • Latest data reveals that Tonix Pharmaceuticals Holding reported EBT of -$136.7 million as of FY2024, which was down 39.20% from -$98.2 million recorded in FY2023.
  • Tonix Pharmaceuticals Holding's 5-year EBT high stood at -$41.2 million for FY2020, and its period low was -$136.7 million during FY2024.
  • In the last 3 years, Tonix Pharmaceuticals Holding's EBT had a median value of -$98.2 million in 2023 and averaged -$107.8 million.
  • Data for Tonix Pharmaceuticals Holding's EBT shows a maximum YoY slumped of 81.86% (in 2020) over the last 5 years.
  • Over the past 5 years, Tonix Pharmaceuticals Holding's EBT (Yearly) stood at -$41.2 million in 2020, then slumped by 79.05% to -$73.7 million in 2021, then fell by 20.07% to -$88.5 million in 2022, then fell by 10.99% to -$98.2 million in 2023, then tumbled by 39.20% to -$136.7 million in 2024.